Collaborations & Alliances

WuXi Biologics, Harbour BioMed in Strategic Mfg. Alliance

WuXi to support the supply of Harbour's products for clinical trials under IND applications

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

WuXi Biologics and Harbour BioMed have entered a strategic collaboration for the development and manufacture of Harbour’s lead HCAb antibody. WuXi Biologics will support the supply of Harbour’s products for clinical trials under Investigational New Drug (IND) applications in China and worldwide.   “In about a year’s time, our scientists have moved our leading HCAb molecule into IND enabling stage. We are excited to collaborate with WuXi Biologics to accelerate further d...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters